Cargando…
Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
Pancreatic neuroendocrine neoplasia constitute an important subentity of the gastroenteropancreatic neuroendocrine neoplasms accounting for up to 15% of all neuroendocrine neoplasm. Prognosis and oncological behavior of pancreatic neuroendocrine tumors (pNETs) is extremely heterogenous and dependent...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771158/ https://www.ncbi.nlm.nih.gov/pubmed/36550801 http://dx.doi.org/10.1097/MD.0000000000032044 |
_version_ | 1784854759206813696 |
---|---|
author | Loosen, Sven H. Kostev, Karel Eschrich, Johannes Krieg, Sarah Krieg, Andreas Luedde, Tom Jann, Henning Roderburg, Christoph |
author_facet | Loosen, Sven H. Kostev, Karel Eschrich, Johannes Krieg, Sarah Krieg, Andreas Luedde, Tom Jann, Henning Roderburg, Christoph |
author_sort | Loosen, Sven H. |
collection | PubMed |
description | Pancreatic neuroendocrine neoplasia constitute an important subentity of the gastroenteropancreatic neuroendocrine neoplasms accounting for up to 15% of all neuroendocrine neoplasm. Prognosis and oncological behavior of pancreatic neuroendocrine tumors (pNETs) is extremely heterogenous and dependent on the specific tumor stage and differentiation. However, systematic data on the specific epidemiology of pNET are scarce. We identified 662 patients with pNET within the Oncology Dynamics database (IQVIA). Patients were derived from 4 European countries (Germany, France, UK, Spain), 3 Asian countries (Japan, China, South Korea) and 2 South American countries (Mexico and Brazil) and with regard to major patient and tumor related characteristics including patients’ age, sex, tumor stage, tumor grading, and differentiation. The mean age of the study cohort was 62 years (SD 12 years) with 53.9.1% of all patients being male. The majority of patients had an Eastern co-operative of Oncology Group 1 performance status (63.3%). The most common Union international contre le cancer tumor stage was stage IV (85%) with liver metastases (89.0%) representing the most common site of extra-pancreatic tumor manifestation. The majority of all patients displayed well or moderate tumor differentiation (9.6% of patients had a Ki-67 expression below 2%. 67.6% of pNET patients had a Ki-67 expression between 2 and 20% and 22.8% of patients showed an expression above 20%). At time point of diagnoses, 93.1% of patients were classified as inoperable. Of note, 93.9 % of patients received systemic anti-tumoral therapy in palliative intention, while treatment was administered in 1.4 % of cases in neoadjuvant and in 4.7% of cases in in an adjuvant setting. Biological therapy was applied to 39.4% of patients, followed by targeted therapies (31.4%) and chemotherapy. Pancreatic neuroendocrine neoplasia are diagnosed in advanced tumor stages, globally. Systemic treatment was the most commonly used treatment modality. Such data may help to better understand the specific epidemiology of pNET worldwide. |
format | Online Article Text |
id | pubmed-9771158 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97711582022-12-22 Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy Loosen, Sven H. Kostev, Karel Eschrich, Johannes Krieg, Sarah Krieg, Andreas Luedde, Tom Jann, Henning Roderburg, Christoph Medicine (Baltimore) 4500 Pancreatic neuroendocrine neoplasia constitute an important subentity of the gastroenteropancreatic neuroendocrine neoplasms accounting for up to 15% of all neuroendocrine neoplasm. Prognosis and oncological behavior of pancreatic neuroendocrine tumors (pNETs) is extremely heterogenous and dependent on the specific tumor stage and differentiation. However, systematic data on the specific epidemiology of pNET are scarce. We identified 662 patients with pNET within the Oncology Dynamics database (IQVIA). Patients were derived from 4 European countries (Germany, France, UK, Spain), 3 Asian countries (Japan, China, South Korea) and 2 South American countries (Mexico and Brazil) and with regard to major patient and tumor related characteristics including patients’ age, sex, tumor stage, tumor grading, and differentiation. The mean age of the study cohort was 62 years (SD 12 years) with 53.9.1% of all patients being male. The majority of patients had an Eastern co-operative of Oncology Group 1 performance status (63.3%). The most common Union international contre le cancer tumor stage was stage IV (85%) with liver metastases (89.0%) representing the most common site of extra-pancreatic tumor manifestation. The majority of all patients displayed well or moderate tumor differentiation (9.6% of patients had a Ki-67 expression below 2%. 67.6% of pNET patients had a Ki-67 expression between 2 and 20% and 22.8% of patients showed an expression above 20%). At time point of diagnoses, 93.1% of patients were classified as inoperable. Of note, 93.9 % of patients received systemic anti-tumoral therapy in palliative intention, while treatment was administered in 1.4 % of cases in neoadjuvant and in 4.7% of cases in in an adjuvant setting. Biological therapy was applied to 39.4% of patients, followed by targeted therapies (31.4%) and chemotherapy. Pancreatic neuroendocrine neoplasia are diagnosed in advanced tumor stages, globally. Systemic treatment was the most commonly used treatment modality. Such data may help to better understand the specific epidemiology of pNET worldwide. Lippincott Williams & Wilkins 2022-12-16 /pmc/articles/PMC9771158/ /pubmed/36550801 http://dx.doi.org/10.1097/MD.0000000000032044 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 4500 Loosen, Sven H. Kostev, Karel Eschrich, Johannes Krieg, Sarah Krieg, Andreas Luedde, Tom Jann, Henning Roderburg, Christoph Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy |
title | Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy |
title_full | Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy |
title_fullStr | Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy |
title_full_unstemmed | Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy |
title_short | Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy |
title_sort | clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771158/ https://www.ncbi.nlm.nih.gov/pubmed/36550801 http://dx.doi.org/10.1097/MD.0000000000032044 |
work_keys_str_mv | AT loosensvenh clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy AT kostevkarel clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy AT eschrichjohannes clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy AT kriegsarah clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy AT kriegandreas clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy AT lueddetom clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy AT jannhenning clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy AT roderburgchristoph clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy |